Pentoxifylline affects cytokine reaction in cardiopulmonary bypass.
| dc.contributor.author | Iskesen I. | |
| dc.contributor.author | Saribulbul O. | |
| dc.contributor.author | Cerrahoglu M. | |
| dc.contributor.author | Onur E. | |
| dc.contributor.author | Destan B. | |
| dc.contributor.author | Sirin B.H. | |
| dc.date.accessioned | 2025-04-10T11:17:11Z | |
| dc.date.available | 2025-04-10T11:17:11Z | |
| dc.date.issued | 2006 | |
| dc.description.abstract | BACKGROUND: Cardiac surgery is associated with an inflammatory response that may cause myocardial dysfunction after cardiopulmonary bypass. We examined the efficacy of pentoxifylline to attenuate the cardiopulmonary bypass-induced inflammatory response during heart operations. METHODS: In a prospective, randomized study, 30 patients undergoing coronary artery bypass graft surgery received either pentoxifylline (group P, n = 15) (continuous infusion of 1.5 mg/kg per hour during operation) or not (group C [control], n = 15). Blood samples for measurements of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and IL-10 were taken from the arterial line in both groups at 5 different time points. RESULTS: TNF-alpha, IL-6, and IL-8 plasma levels increased in both groups after cardiopulmonary bypass, with a higher increase in the control group (P < .05). CONCLUSIONS: Our results indicate that pentoxifylline infusion during cardiac surgery inhibits the proinflammatory cytokine release caused by cardiopulmonary bypass. | |
| dc.identifier.DOI-ID | 10.1532/hsf98.20061090 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/52403 | |
| dc.title | Pentoxifylline affects cytokine reaction in cardiopulmonary bypass. | |
| dc.type | Article |